Charles River Laboratories International, Inc. CRL
292.84
(1.60)
(0.54%)
as of 25 Sep
- Market cap
- $14.1B
- P/E
- 0.0×
Follow CRL
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Charles River Laboratories International, Inc. (CRL) P/S ratio
As of 25 September 2026, Charles River Laboratories International, Inc. (CRL) trades at a P/S ratio of 3.5×. Over the past ten years it has ranged from 1.3× (April 2025) to 7.0× (September 2021); the current reading is higher than 85% of that period. That is below the Diagnostics & Research industry median of 4.9× and below the Healthcare sector median of 3.8×.
P/S ratio, daily
Annual
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 2.5× | 5.14% |
| FY2024 | 2.3× | (19.41%) |
| FY2023 | 2.9× | 4.12% |
| FY2022 | 2.8× | (47.86%) |
| FY2021 | 5.4× | 26.42% |
| FY2020 | 4.2× | 49.10% |
| FY2019 | 2.8× | 18.59% |
| FY2018 | 2.4× | (15.33%) |
| FY2017 | 2.8× | 32.18% |
| FY2016 | 2.1× | (21.95%) |
Quarterly
| Period | P/S ratio | Change |
|---|---|---|
| Jun 2026 | 2.7× | 29.88% |
| Mar 2026 | 2.1× | (14.84%) |
| Dec 2025 | 2.5× | 28.67% |
| Sep 2025 | 1.9× | 3.38% |
| 42 more quarters | Free account |
Against its own ten years
Low 1.3×
High 7.0×
Ten-year median
2.7×
Current reading's percentile
85
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| ICLR ICON PLC compare | 1.6× |
| LH Labcorp Holdings Inc. compare | 1.8× |
| DGX Quest Diagnostics Incorporated compare | 2.3× |
| CRL Charles River Laboratories International, Inc. | 3.5× |
| QGEN QIAGEN N.V. compare | 4.3× |
| RVTY Revvity Inc. compare | 5.8× |
| MEDP Medpace Holdings, Inc. compare | 6.3× |
| GH Guardant Health, Inc. compare | 19.9× |
| TWST Twist Bioscience Corporation compare | 26.5× |
| Diagnostics & Research industry median | 4.9× |
| Healthcare sector median | 3.8× |
| Market median | 2.0× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on CRL
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement